Specifically, oral administration of TQ (20 mg/kg) enhanced the effectiveness of cisplatin in hepatocellular carcinoma (HCC) treatment by regulating the GRP78/CHOP/caspase-3 pathway [76]. This evidence concerns the gene DDIT3 and hepatocellular carcinoma.